Background. An optimal haemoglobin (Hb) response to erythropoietin requires elevated iron indices in dialysis patients; however, it is unknown if the same applies in chronic kidney disease (CKD). , P=NS. For patients (Groups A and B, n=27 in each group) whose creatinine regression slope increased (indicating worsening function), the fall in Hb over 12 months also did not differ between groups despite adequate separation in iron indices. Serious adverse events overall did not differ between groups. Conclusions. Elevated iron indices did not increase Hb synthesis in ESA-naive, iron replete, pre-dialysis patients with Hb >110 g/L.
Introduction
The use of intravenous (IV) iron to maintain elevated iron indices and achieve a more efficient response to erythropoietin-stimulating agents (ESA) has been well described in dialysis patients [1] [2] [3] . For pre-dialysis (but ESA-dependent) patients with chronic kidney disease (CKD), studies are both infrequent and less conclusive, with some reports suggesting that the ESA response to IV iron administration is comparable to oral replacement [4, 5] . Such findings can be interpreted to indicate either that a less uraemic milieu in (pre-dialysis) CKD patients enables a better haemopoietic response to an ESA (or possibly native erythropoietin) with only modest increases in iron availability, or that marginal iron deficiency is common in CKD patients and iron replacement will result in a higher haemoglobin (Hb) regardless of how it is administered.
Studies pertaining to both possibilities are sparse. Furthermore, the prevalence of iron deficiency has not been well studied in CKD, although menstruation, previous childbirth and a reduction in red meat intake with the onset of established uraemia could well result in at least marginal iron stores in many patients before commencing dialysis. Similarly, it is unknown whether maintaining supra-physiological iron indices in these patients before the development of significant anaemia would, independently, preserve or even increase their Hb concentration. We therefore performed a multi-centre, randomized, controlled trial in stable and otherwise well CKD patients, in order to assess the effects of elevated (using IV iron sucrose) compared to physiological iron indices on Hb concentrations for a period of 12 months.
Subjects and methods
The study was conducted at six centres in Australia following local ethics committee approval. There were 124 subjects screened for the study; 100 were randomized and 85 completed the study ( Figure 1 ). All patients were screened to ensure they were eligible based on the following criteria:
(i) Inclusion criteria: 18-80 years; Hb ≥110 g/L; Stages 3-5 CKD, but calculated cr.cl. ≤35 mL/min (≤50 mL/min diabetics); dialysis independent; and clinically significant rise in creatinine and/or fall in Hb concentration in past 18 months.
(ii) Exclusion criteria: currently using an ESA; iron overload: ferritin >300 µg/L and transferrin saturation (TSat) >25%; severe iron deficiency: ferritin <30 µg/L and TSat <15%; active malignancy, haemolysis or gastrointestinal bleeding; persistent sepsis or significant chronic inflammation [C-reactive protein (CRP) >25 mg/L]; severe uncontrolled ischaemic heart disease or congestive heart failure; and adult polycystic kidney disease.
After obtaining informed consent, subjects were assigned to one of two treatment regimens.
Group A patients were given IV iron sucrose (Venofer, Vifor International Inc, Switzerland) at doses of 100-200 mg every 2 months to maintain a ferritin concentration of 300-500 µg/L and/or TSat of 25-50%. The first dose of IV iron sucrose (including test dose) was given in an area where resuscitation facilities were available. Thereafter, IV iron sucrose was administered bimonthly via slow IV bolus in the hospital outpatient clinic or physician's consulting rooms. Thirty-four patients required a monthly injection on one or more occasions to reach or maintain the Group A target.
Group B patients were given oral iron tablets (325 mg ferrous sulphate= 105 mg elemental iron) as required to maintain ferritin concentrations between 100 and 150 µg/L and/or a TSat of 20-25%. Six subjects required no oral iron to maintain target values, five subjects were intolerant of oral iron and were given infrequent doses of 100 mg IV iron to achieve target, nine subjects required oral iron for the entire time they were enrolled, and 28 subjects started and stopped oral iron therapy at different visits over their enrolment period.
Baseline data included age, race, gender, cause of CKD, body mass index (BMI), blood pressure (BP), heart rate, vitamin B12 and folate concentrations, medical history and current medications. Every 2 months, weight, BP, heart rate, full blood examination, kidney function Maintenance of elevated versus physiological iron indices in non-anaemic patients with CKD(creatinine and Cockroft-Gault calculated creatinine clearance), iron studies and CRP were monitored. Liver function and parathyroid hormone (PTH) concentrations were checked at baseline, 6 and 12 months. eGFR was calculated according to the standard MDRD formula [6] .
Statistical analysis
Block randomization lists were generated with Graphpad Statmate, Version 3.0 (GraphPad Software, Inc, San Diego, CA 92121, USA), and simple block randomization was used to ensure a balance of treatment groups across the sites. The primary endpoint was defined as the change in Hb concentration at 12 months or at termination (dialysis, commencement of an ESA and adverse event). Minimum permitted enrolment duration for protocol completion was 6 months. Secondary endpoints included changes in renal function (calculated creatinine clearance and eGFR*), quality of life, time taken to commence dialysis and the time from randomization to the requirement of an ESA. (*: Estimates of glomerular filtration rate (eGFR) were not widely in use at study commencement, so modified MDRD values have been provided post hoc to accord with current practise [6] .) Sample size calculations were as follows: the difference in mean Hb concentration between groups was expected to be at least 7.5 g/L (0.75 g/ dL), which is also the lowest meaningful clinically distinguishable difference. Based on past local studies, the standard deviation (SD) in Hb concentrations was, conservatively, expected to be 10 g/L (1.0 g/dL) [7] . With an alpha level of 0.05 and a predictive power of 0.90 to test the hypothesis, the number of patients required to complete the study, n, was calculated to be 76. One hundred patients were randomized, with 15 patients censored.
Results are presented using mean±SD or median and inter-quartile range (IQR). Missing values in the study data were replaced using the 'last observation carried forward' technique. Prospectively, it was decided that data on patients who commenced an ESA or dialysis within 6 months of commencing the study or who died at any time during the study were censored. For the analysis of differences between the two treatment groups, the two-sided Wilcoxon test (with t approximation, alpha level 5%) and chi-square analysis were used. Paired (withingroup) comparisons were made using the paired t test. No adjustment of P values was implemented due to the exploratory nature of the study, which was not used for performing confirmatory analyses. Spearman correlation coefficients and the respective P values were reported when displaying results of correlation analyses. All analyses were performed using SAS ® version 8.2 (SAS Institute Inc, Cary, NC, USA). In addition to baseline and dropout data for all randomized patients (n=100), results are presented for those patients achieving protocol (n=85) and for those completing 12 months (n=77). Additional selected subgroup data are also presented.
Results

Overall data
Demographic and baseline clinical data of the 100 randomized patients are shown in Table 1 .
The majority of patients were aged over 60 years, were overweight, male, Caucasian and using ACE inhibitors. Approximately 50% of patients were diabetic. Neither the presence of type 2 diabetes (n=47, 21 Group A) nor the use of ACE inhibitors (n=96, 51 Group A) differed between groups. There was no difference in Hb concentrations at any time point when patients with diabetes or taking ACE inhibitors were compared with those who did not (data not shown). Blood pressure levels were mostly controlled initially, although subject to considerable individual variability.
Eighty-five patients achieved protocol (43 Group A) and 77 patients completed 12 months' appraisal (39 Group A). There were five deaths in Group A and one in Group B (P = 0.2). The first three deaths in Group A occurred within the first 4 months; the latter two deaths each occurred at month 10. The death in Group B was in the first month. None of the deaths was considered related to study participation. Three patients in Group B (compared to one in Group A) commenced an ESA, and three (compared to one) commenced dialysis at different times during the study (Figure 1 ). There was no meaningful (or statistical) difference between groups for death, progression of CKD or dialysis dependency taken either individually or together as a composite endpoint (data not shown).
Protocol achieved (n=85)
Randomization and termination data for each group are presented in Table 2 (Group A=43, Group B=42). Initial mean Hb concentration was 119±7 vs 116±12 g/L, with little change in means and no difference between groups at study end, despite significant increases in ferritin and TSat. At randomization, most patients' Hb (n=52) was between 110 and 120 g/L. By study end, this number had declined to 35, with 21 of the patients demonstrating a Hb <110 g/L. Group B appeared to show a more consistent spread of Hb across the defined ranges throughout the study.
Functional and/or absolute iron deficiency was evident in 37 (Group A) and 42% (Group B) of patients at study commencement. This had declined to 12 and 36%, respectively, by study end, with most affected patients functionally deplete. Ferritin and TSat showed significant and substantial differences between and within groups by study end.
Renal function did not change appreciably during the study. Although the median creatinine in Group B increased from 230 to 272 µmol/L, the change in eGFR was slight. There was little change numerically in CKD stage during the study, with only one of the 85 patients who achieved protocol commencing dialysis.
CRP and albumin concentrations were within the normal range for almost all patients at each measured time point (6-month data not shown). PTH concentrations were elevated at study commencement and trended higher during the study but were not different between groups.
Subgroup analysis
Group A patients (n = 27) whose creatinine regression slope increased over the 12 months (indicating worsening renal function) were compared with their Group B counterparts (n = 27). Despite adequate separation in iron indices for both ferritin (176±79, Group A, vs 118±68 µg/L, P=0.003) and TSat (27±9 vs 23±6%, P=0.02) apparent by months 2 and 6, respectively, there was no difference in Hb between these groups throughout the 12-month period. The overall mean fall in Hb over 12 months in these subgroups was 5 g/L for Group A (117±6-112± 7 g/L) and 3 g/L for Group B (120±9-117±13). No differences between subgroups were identified for creatinine, CRP, systolic or diastolic blood pressure (data not shown).
Completed 12 months (n=77)
Progressive results for patients who completed 12 months of treatment are displayed in Figure 2 and Table 3 (Group A=39, Group B=38).
There was no initial difference between groups for Hb, ferritin or TSat; however, ferritin was higher in Group A by month 4 (245 ± 100 vs 156 ± 95 µg/L, P <0.001) and TSat by month 6 (26±6 vs 22±6%, P=0.01). These differences were maintained for the rest of the study. Hb did not differ between groups at any time. IQR, inter-quartile range; TSat, transferrin saturation; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; CRP, C-reactive protein. †, P < 0.001; ‡, P < 0.01; ь, P < 0.05; İ, P < 0.10: within-group comparisons, randomization vs end protocol. *, P < 0.001; џ, P < 0.05; İ, P < 0.10: between-group comparisons, end protocol. All other P values were >0.20.
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There was little change in renal function in either group during the study. Most patients began and ended the 12 months with stage 4 CKD, although some did deteriorate to stage 5. PTH concentrations were slightly raised at randomization but did not deteriorate. CRP and albumin levels were normal throughout. Blood pressure was well controlled overall, although substantial variation was evident in individual patients.
Correlations
No correlation was found between Hb concentration and other variables (including age, blood pressure, ferritin, TSat, creatinine or CRP), although the regression slope for the change in Hb (ΔHb) vs change in creatinine showed a strong inverse relationship (r=−0.393, P<0.0001). No meaningful correlation was found for the other parameters when plotted against ΔHb. Ferritin levels correlated closely with TSat (r=0.337, P=0.003).
Discussion
We report the results of a prospective, open-label, multicentre, randomized controlled trial (RCT) of raised compared to normal iron indices in patients with Hb concentrations ≥110 g/L, CKD Stages 3-5. The principle finding is that maintaining iron stores above physiological levels does not appear to confer an advantage in Hb concentration for these patients. Significant and substantial differences were evident in iron parameters within the first half of the study, yet Hb concentrations between groups did not differ at any time up to and including the primary endpoint (12 months or termination after at least 6 months).
It is possible that the stability of both Hb and creatinine throughout the study masked a potential advantage from the elevated iron indices for Group A patients. Hb and renal function fell only marginally during the 12 months, despite patients having been selected for demonstrating a fall of at least 10 g/L in Hb and/or a clinically significant rise in creatinine over the previous 18 months. Assuming a similar rate of fall of Hb during the study, a required sample size of 76 patients was calculated. However, with the observed fall in mean Hb and SD,~8000 patients would have been required to have demonstrated a significant advantage. Despite these reservations, not even a slight trend in Hb in favour of Group A patients was evident during the study, and even for those patients who showed a progressive rise in creatinine, the mean fall in Hb concentration in the 27 Group A patients (5 g/L) was similar to their equalnumbered counterparts in Group B (3 g/L).
It is not clear whether the use of an ESA would have resulted in higher Hb concentrations if used in Group A compared to Group B patients, although the current guidelines for ESA use in many countries now preclude initiating treatment when Hb concentrations are above 110 g/L, which was one of the study's entry criteria [8] [9] [10] . Similarly, whether patients would have benefited from higher iron indices if they were more anaemic is unknown, but is a possibility. Inhibition of erythropoiesis due to an increasingly uraemic milieu-usually approximated to a decline in eGFR (or more broadly the CKD stage)-might also of itself affect the haematopoietic response to available iron. It is well known that dialysis patients respond more efficiently to elevated iron indices [1] [2] [3] , but at what point in the decline of kidney function this becomes clinically relevant is uncertain, as is the comparative contribution of concurrently worsening anaemia. Erythropoietin concentrations are usually-although not sufficiently-elevated in patients with CKD, particularly as the Hb starts to fall. Most patients in the current study were stage 4 CKD, but none had Hb concentrations below 110 g/L. What does therefore appear likely is that non iron-deficient patients with this level of renal impairment and an Hb concentration above 110 g/L are unlikely to increase their Hb in response to elevation of their iron indices beyond standard parameters. Where overt iron deficiency does exist, correction of stores with IV or oral iron can be considered. In doses calculated according to lean body weight in adults, IV iron avoids gastrointestinal complications and is far more efficient than oral treatment. In this study, and from anecdotal reports for many years, the risk of adverse events appears very low with agents such as iron sucrose.
The few comparative studies which have addressed the response of IV compared to oral iron in patients who were clearly anaemic-invariably Hb concentrations below 110 g/L-have had mixed results. In an 8-week RCT, Van Wyck et al. found an advantage in IV iron sucrose (1000 mg over 14 days) over high dose oral iron (325 mg thrice daily for 56 days) in 161 iron replete but anaemic (initial mean Hb, 102 vs 101 g/L) CKD subjects [11] . With a clear separation in iron indices, a 44 vs 28% increase in Hb (defined as a rise of at least 10 g/L) in the IV Group was found. Interestingly, the concurrent use of an ESA appeared to make no difference to the Hb response. In contrast, Charytan and co-workers did not find a greater increase in Hb with IV iron sucrose compared to oral iron in a 6-week RCT in 102 anaemic subjects (mean Hb, 97 vs 98 g/L) of similar demographic characteristics [4] . However, both ferritin and TSat were higher in the IV Group at study end, 60% of patients achieving a combined endpoint of an increase of at least 8 g/L in Hb and a ferritin ≥160 µg/L (compared to no change in the group receiving oral iron). Similar results had been reported by Stoves et al. in a 6-month study, although all patients were treated concurrently with an ESA and the required doses of the ESA showed no difference between groups [5] . In a short and uncontrolled study, Silverberg et al. showed a greater increase in Hb in anaemic CKD patients (haematocrit <35%, creatinine clearance 10-40 mL/min/1.73 m [2] ) who were administered both IV iron and subcutaneous epoetin alfa, compared to those who were administered IV iron only [12] . In a follow-up study of the same patients, one-third of patients (n=24) was able to maintain a haematocrit above 35% with IV iron only (maintaining ferritin concentrations <400 µg/L and TSat <40%) for a period of 12 months [13] . Finally, in a recent short study by Spinowitz et al., IV iron ferumoxytol was found superior to oral iron in non-dialysis CKD patients, elevating Hb by 8.2±12.4 compared to 1.6±10.2 g/L over 35 days [14] . However, over 30% of patients were receiving an ESA and, although not stated, the population appeared to comprise patients with and without iron deficiency (mean ferritin concentrations of 146.1±173.6 and 143.5 ± 114.9 µg/L and TSat 11.3 ± 6.1 and 10.1 ± 5.5% in respective groups) at baseline.
It is known that the iron indices used in this current study are not necessarily ideal estimates of iron stores or availability, even if they are the parameters most widely used and most commonly referred to. Other parameters, such as reticulocyte haemoglobin content (CHr), have been shown to be better markers of iron status in dialysis patients, at least in response to ESA, although Van Wyck et al. demonstrated little relationship between baseline iron indices, including CHr, and the subsequent change in Hb after IV iron in his study in pre-dialysis (CKD stages 3-5) patients [11] . IV iron nonetheless appeared to confer some advantage in most studies in anaemic patients with stages 3-5 CKD [4, 13, 15] . Thus, it is possible that anaemia itself might be the most reliable guide to the need for iron supplementation in the CKD group, even if there is no evidence of overt iron deficiency.
In summary, data from this study suggest that there is little, if any, advantage in elevating iron indices above the physiological range in patients with advanced CKD (Stages 3-5) when the Hb concentration is above 110 g/ L. However, once anaemia develops, most studies have found a significant benefit (usually with IV iron administration) from elevating iron indices-either with or without the concurrent use of an ESA-in order to increase Hb concentrations. Data are presented in respective groups. SD, standard deviation; IQR, inter-quartile range; TSat, transferrin saturation; Calc.Cr.Cl., calculated creatinine clearance (Cockroft-Gault); eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; CRP, C-reactive protein; MSSBP, mean seated systolic blood pressure; MSDBP, mean seated diastolic blood pressure. †, P<0.001; ‡, P < 0.01: within-group comparisons, randomization vs 6 or 12 months. *, P < 0.001; , P < 0.01: between-group comparisons, at 6 or 12 months. All other P values were >0.20.
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